N-[4-(1H-pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides and their use as pharmaceuticals

A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a pharmaceutically acceptable salt thereof,

• wherein
• Ar is selected from the series consisting of 2,5-difluorophenyl, 2-fluorophenyl, 2-chloro-3,5-difluorophenyl, 2-chloro-4-fluorophenyl, 2-chloro-4,5-difluorophenyl, 2-chloro-3-fluorophenyl, and 2-chlorophenyl;
• n is selected from the series consisting of 0, 1 and 2;
• R1 is selected from the series consisting of hydrogen, —N(R11)-R12, —N(R13)-C(O)—R14,—N(R13)-S(O)2—R15, —N(R13)-C(O)—NH—R14, —C(O)—N(R16)-R17, —CN, (C1-C4)-alkyl and —(C1-C4)-alkyl-O—R18;
• R2 is selected from the series consisting of halogen, (C1-C4)-alkyl, —O—(C1-C4)-alkyl and —CN;
• R11 and R12 are independently of one another selected from the series consisting of hydrogen, (C1-C4)-alkyl, (C3-C7)-cycloalkyl and —(C1-C4)-alkyl-(C3-C7)-cycloalkyl,
• or R11 and R12, together with the nitrogen atom carrying them, form a monocyclic, 4-membered to 7-membered, saturated heterocycle which, in addition to the nitrogen atom carrying R11 and R12, comprises 0 or 1 further ring heteroatom selected from the series consisting of nitrogen, oxygen and sulfur, and which is unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of fluorine and (C1-C4)-alkyl;
• R13 is selected from the series consisting of hydrogen, (C1-C4)-alkyl and (C3-C7)-cycloalkyl;
• R14 and R15 are independently of one another selected from the series consisting of (C1-C8)-alkyl, (C3-C7)-cycloalkyl, —(C1-C4)-alkyl-(C3-C7)-cycloalkyl, phenyl, —(C1-C4)-alkyl-phenyl, Het and —(C1-C4)-alkyl-Het, wherein phenyl and Het all are unsubstituted or substituted by one or more identical or different substituents R30;
• R16 is selected from the series consisting of hydrogen, (C1-C4)-alkyl and (C3-C7)-cycloalkyl;
• R17 is selected from the series consisting of hydrogen, (C1-C8)-alkyl, (C3-C7)-cycloalkyl, —(C1-C4)-alkyl-(C3-C7)-cycloalkyl, phenyl, —(C1-C4)-alkyl-phenyl, Het and —(C1-C4)-alkyl-Het, wherein phenyl and Het all are unsubstituted or substituted by one or more identical or different substituents R30,
• or R16 and R17, together with the nitrogen atom carrying them, form a monocyclic, 4-membered to 7-membered, saturated heterocycle which, in addition to the nitrogen atom carrying R16 and R17, comprises 0 or 1 further ring heteroatom selected from the series consisting of nitrogen, oxygen and sulfur, and which is unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of fluorine and (C1-C4)-alkyl;
• R18 is selected from the series consisting of hydrogen and (C1-C4)-alkyl;
• R30 is selected from the series consisting of halogen, (C1-C4)-alkyl, —O—(C1-C4)-alkyl and —CN;
• and
• Het is a monocyclic, 4-membered to 7-membered, saturated, partially unsaturated or aromatic heterocycle which comprises 1 or 2 identical or different ring heteroatoms selected from the series consisting of nitrogen, oxygen and sulfur, and which is bonded via a ring carbon atom;
• wherein all cycloalkyl groups can be substituted by one or more identical substituents selected from the series consisting of fluorine and (C1-C4)-alkyl;
• wherein all alkyl groups, independently of any other substituents which can be present on an alkyl group, can be substituted by one or more fluorine substituents.